Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program
The collaboration builds on the ongoing Phase 1a/b dose escalation and expansion clinical trial (NCT06021626) currently underway at MSK for sarcoma and Merkel cell carcinoma patients, and aims to explore the potential of CRD3874-SI in treating additional types of cancer. Through the MSK Therapeutics Accelerator program, MSK will provide Curadev with expertise and institutional resources, including medical, clinical, and regulatory advice, to further the development of CRD3874-SI. This expanded collaboration marks a significant milestone in translating promising STING pathway research into broader clinical application and will be overseen by William Tap, MD, Chief of the Sarcoma Medical Oncology Service at MSK, and Ciara Kelly, MBBCh BAO, Interim Clinical Director of MSK's Sarcoma Oncology Service.
Dr. William Tap said, "MSK and its Division of Solid Tumors are excited to co-develop CRD3874-SI, a novel first-in-class allosteric STING agonist, with Curadev. CRD3874-SI has demonstrated an encouraging safety and efficacy profile in a first-in-human study at MSK. CRD3874-SI is moving forward into multiple solid-tumor expansion cohorts, guided by disease specific experts and the support and structure of the MSK Accelerator Program, which is designed to enhance and expedite the development of novel compounds across malignancies. CRD3874-SI has the potential to offer patients a new treatment option with continued innovation and exploration of the benefits of immunotherapy in cancer care."
Dr. Arjun Surya, Co-founder and CEO of Curadev, added, "We are encouraged by the early readouts with CRD3874-SI systemic monotherapy from our ongoing clinical trial in patients with treatment refractory cancers at MSK and are honored by the opportunity to deepen our collaboration through the MSK Therapeutics Accelerator program. The research and development collaboration between oncologists at MSK and the inventors of CRD3874-SI at Curadev could become a role model for advancing bench to bedside medicines.
MSK's historic leadership position in the development of cancer immunotherapy and the exemplary dedication of the oncologists we work with is inspiring and make it an ideal partner in Curadev's effort to investigate the therapeutic potential of its systemically administered allosteric STING agonist in patients with advanced/metastatic cancer."
About Curadev
Curadev is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapeutics for treating intractable diseases. Curadev has built an impressive portfolio of discovery research programs using a target-centric approach, innovative screening schemes, and traditional wet-lab chemistry and pharmacology, resulting in patent-protected drug candidates that modulate next-generation drug targets. Curadev Pharma, Inc., the US-based clinical development subsidiary founded in 2021, is currently leading the Phase1/2 trials of STING agonist assets under a US FDA-approved IND application. For more information, visit www.curadev.in.
MSK's Therapeutics Accelerator program is a strategic partnership program between MSK and biotechnology companies to advance novel cancer therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK's community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on the treatment or management of cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
40 minutes ago
- Cision Canada
Young Mother's Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC
VANCOUVER, BC, /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to rheumatoid arthritis (RA) treatment by removing barriers that prevent patients from accessing the medications they truly need—barriers not found in many other provinces. Diagnosed with seropositive rheumatoid arthritis at just 29 years old, Eileen spent years searching for answers while coping with disabling pain, extreme fatigue, and the emotional toll of chronic illness. "By the time I was diagnosed, I was on the verge of being placed on long-term disability," Eileen recalls. "I had a toddler at home and every day was a struggle just to care for him." Forced to Wait While Suffering Like many RA patients in BC, Eileen's path to relief was slowed by a policy known as Step Therapy. Under Step Therapy, patients are required to try and 'fail' on older, less effective medications—sometimes for a year or more—before they can access modern treatments like biologics that offer the best chance for remission. "My doctor and I both knew these medications weren't likely to work for me, but we had no choice," Eileen says. "All that time, my disease kept progressing, and my hope for a normal life was slipping away." Eliminating these treatment delays remains a key priority for Arthritis Society Canada, the national organization leading advocacy, research, and support for the six million Canadians with arthritis. "There is no cure for arthritis. And because arthritis medications often require trial and error to find what works, speed of access is critical in preventing irreversible damage," says Trish Barbato, President and CEO of Arthritis Society Canada. "What works for one person may not work for another, and people often become resistant to treatment over time, making timely access to a range of medications even more essential." Eileen's story is far from unique. Arthritis is the leading cause of disability in North America, affecting people of all ages, and early access to the right treatment is critical. Yet in BC, restrictive policies leave many patients—especially younger adults—facing avoidable disability, work loss, and deteriorating health. A Personal and Systemic Cost The impact goes beyond the individual. Untreated or undertreated RA can lead to irreversible joint damage, increased healthcare use, and higher costs for the system as a whole. "If I'd had access to effective treatment earlier, I might still be working full-time," says Eileen. "Instead, I lost years to pain and fatigue, and my disease progressed much faster than it needed to." MedAccessBC Calls for Policy Change Eileen's experience underscores a larger, systemic issue that the Medicines Access Coalition – BC (MedAccessBC) has been fighting to address for over two decades. "Forcing patients to fail on older medications before approving access to newer, proven treatments is not only out of step with medical evidence—it's unfair and costly in the long run," says Jamie Myrah, Co-Chair of MedAccessBC. "All British Columbians deserve the opportunity for the best possible health outcomes, not arbitrary delays." As a non-profit coalition representing over 30 patient care organizations, MedAccessBC urges the BC government to review and update Step Therapy policies for rheumatoid arthritis and similar chronic conditions, ensuring that treatment decisions prioritize patient well-being and clinical best practices. A Call to Action Eileen's message to policymakers is clear: "Please give people like me a fighting chance to live, work, and participate fully in our communities. Timely access to the right medication isn't a luxury—it's a lifeline." About Rheumatoid Arthritis (RA) Rheumatoid arthritis is an autoimmune disease that causes the body's immune system to attack healthy joints and tissues. It can strike at any age and leads to pain, swelling, and fatigue. If not treated effectively and early, RA can result in severe disability, organ complications, and reduced life expectancy. There are more than 100 types of arthritis and related autoimmune conditions, affecting millions of Canadians. (Arthritis Society Canada) About the Medicines Access Coalition of BC MedAccess BC advocates for improved access to medications and health technologies for individuals with chronic diseases. Representing over 30 patient organizations, it has been working since 1997 to improve access to evidence-based medicines through BC's PharmaCare program. About Arthritis Society Canada Arthritis Society Canada represents the six million people in Canada living with arthritis today, and the millions more who are impacted or at risk. Fueled by the trust and support of our donors and volunteers, Arthritis Society Canada is fighting arthritis with research, advocacy, innovation, information and support. We are Canada's largest charitable funder of cutting-edge arthritis research. We will not give up our efforts until everyone is free from the agony of arthritis. Arthritis Society Canada is accredited under Imagine Canada's Standards Program. For more information, visit
Cision Canada
40 minutes ago
- Cision Canada
NEVADA KING ANNOUNCES RESULTS OF SHAREHOLDER MEETING AS WELL AS BOARD AND MANAGEMENT CHANGES
VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Nevada King Gold Corp. (TSXV: NKG) (OTCQB: NKGFF) (" Nevada King" or the " Company") is pleased to announce that, at its meeting of Shareholders (the " Shareholders") held today, August 14, 2025, Shareholders approved the re-election of Collin Kettell and William Hayden to the Board of Directors (the " Board") of the Company . In addition, John Sclodnick and Michael Doolin were elected to the Board. Former directors Paul Matysek and Craig Roberts did not stand for re-election. Effective immediately, Mr. Sclodnick will serve as the Company's Chief Executive Officer replacing Collin Kettell, who remains a Director of the Company. Mr. Kettell was appointed Chairman on the date hereof. In addition, the Company announces the appointment of Jeff Stieber as the Company's Chief Financial Officer, following the resignation of Bassam Moubarak. "On behalf of the company, I'd like to thank Paul Matysek, Craig Roberts, and Bassam Moubarak for their significant contributions since inception. We wish them all every success in their future endeavours", stated Mr. Kettell. "I am also pleased to welcome Jeff Stieber, whose senior leadership experience across exploration, development, and production stages will be invaluable as we advance our Atlanta project, and I'm excited to see John Sclodnick take over the role as CEO of the Company. Over the past year, working closely with John has strengthened my confidence in his leadership, which has already helped drive increased institutional ownership. As Founder and Chairman, I am confident the Company is on a strong path forward under his guidance and I look forward to working in tandem with him to advance Nevada King." Mr. Sclodnick, CEO stated: "It is an exciting time for Nevada King, with exploration momentum building across a number of highly prospective targets at our Atlanta project, to complement our high-grade and high-confidence resource. I'm eager to continue to build that momentum alongside our dedicated and energized team, to advance these targets, generate significant discoveries, and create real value for our shareholders." All other matters put forward before the Shareholders at the meeting for consideration and approval, including the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditor of the Company at a remuneration to be fixed by the Board, and renewal of the stock option plan of the Company, as set out in the Company's Management Information Circular dated July 4, 2025, were approved. With more than 35 years of experience in the mining industry, Mr. Doolin has led various companies in driving operational efficiency. At Karora Resources Inc., he served as Senior Vice President of Technical Services and was a key player in increasing the company's throughput from 340,000 to 1.6 million tonnes per annum, which was a significant factor in its successful merger. In his capacity as Chief Operating Officer of Klondex Mines Ltd., he played a crucial role in raising gold production from 8,000 to 200,000 ounces per year, which contributed to the company's acquisition by Hecla Mining Company. Mr. Doolin has also held Chief Executive and Chief Operating Officer positions at Silver Elephant Mining, as well as leadership roles as Mill Manager at Great Basin Gold and Metallurgical Lab Lead at McClelland Labs. He currently serves as Chief Operating Officer of Americas Gold and Silver Corporation and Culico Metals Inc. Jeff Stieber Mr. Stieber has over 19 years of experience in finance, accounting, and strategy, having held senior executive roles with Hycroft Mining, Klondex Mines, Tahoe Resources, White Pine Precious Metals, and Bendito Resources. He is knowledgeable in all phases of mining project development, from guiding exploration-stage projects to advancing development assets into production and cash flow generation. Mr. Stieber is a Certified Public Accountant in the State of Nevada and a Certified Financial Modeling & Valuation Analyst. He also currently serves as a director for Chesapeake Gold Corp. About Nevada King Gold Corp. Nevada King is focused on advancing and growing its 100% owned, past producing, 130km 2 Atlanta Gold Mine project located along the Battle Mountain trend in southeast Nevada. The project hosts an NI 43-101 compliant pit-constrained oxide resource of 1,020koz Au in the measured and indicated category (27.7M tonnes at 1.14 g/t) plus an inferred resource of 99koz Au (3.6M tonnes at 0.84 g/t). See the NI 43-101 Technical Report titled "Technical Report and Estimate of Gold and Silver Mineral Resources for the Atlanta Project, Lincoln County, Nevada, USA" with an effective date of September 6, 2024, and a report date of July 18, 2025, as prepared by RESPEC (formerly Mine Development Associates) and filed under the Company's profile on SEDAR+ NI 43-101 Mineral Resources at the Atlanta Mine by RESPEC 2025 Please see the Company's website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statements Regarding Forward Looking Information This news release contains certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operations and activities of Nevada King, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or" should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by Nevada King, are inherently subject to significant business, economic, technical, geologic, environmental, regulatory, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability to complete proposed exploration work, the results of exploration, continued availability of capital, and changes in general economic, market and business conditions. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these items. Nevada King does not assume any obligation to update forward-looking statements should beliefs, opinions, projections, or other factors, change, except as required by applicable securities laws. SOURCE Nevada King Gold Corp.
Cision Canada
40 minutes ago
- Cision Canada
Various brands of Pistachio & Knafeh Milk Chocolate recalled due to Salmonella
OTTAWA, ON, Aug. 14, 2025 /CNW/ - Product: Pistachio & Knafeh Milk Chocolate Issue: Food - Microbial contamination - Salmonella Distribution: Online British Columbia Ontario Quebec See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)
